A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs DP 001 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Proof of concept; Therapeutic Use
- Sponsors Deltanoid Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 14 Oct 2015 According to a Deltanoid Pharmaceuticals media release, results from this study will be presented at the American Society of Nephrology meeting.
- 04 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.